Atmo Biosciences Reaches Primary Endpoints in Pivotal Clinical Study for Initial Indication
April 09, 2024
April 09, 2024
ST. LOUIS PARK, Minnesota, April 9 [Category: Medical] -- Medical Alley posted the following news release:
Primary endpoints reached in a multi-site pivotal clinical trial
Data will support a regulatory submission with the FDA in Q2 CY2024 for an initial indication in gastrointestinal motility disorders.
Melbourne, Sydney, San Diego - 10th April 2024
Atmo Biosciences, a company commercializing the world's first ingestible gas-sensing capsule . . .
Primary endpoints reached in a multi-site pivotal clinical trial
Data will support a regulatory submission with the FDA in Q2 CY2024 for an initial indication in gastrointestinal motility disorders.
Melbourne, Sydney, San Diego - 10th April 2024
Atmo Biosciences, a company commercializing the world's first ingestible gas-sensing capsule . . .